Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Keli LimaDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0002-5498-7539
César Alexander Ortiz RojasDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0003-3420-803X
Frederico Lisboa NogueiraDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0003-1337-7635
Wellington Fernandes da SilvaDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0001-5958-3181
Rita de Cássia CavaglieriDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.
Luciana NardinelliDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.
Aline de Medeiros LealDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.
Elvira Deolinda Rodrigues Pereira VellosoDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0002-9707-0579
Israel BenditDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0002-4751-1428
João Agostinho Machado-NetoDepartment of Pharmacology, Institute of Biomedical Sciences University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0002-2937-8109
Eduardo Magalhães RegoDepartment of Internal Medicine, Hematology Division, Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculdade de Medicina University of São Paulo Sao Paulo Brazil.ORCID https://orcid.org/0000-0003-1567-4086
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Clinical significance of Philadelphia-like-related genes in a resource-constrained setting of adult B-acute lymphoblastic leukemia patients. · full record | OpenQuestion